Condition: Acute Lymphoblastic Leukemia · Mixed Phenotype Acute Leukemia · Sponsor: Princess Maxima Center for Pediatric Oncology
This study is a treatment protocol with blinatumomab for infants under 1 year old who are diagnosed with acute lymphoblastic leukemia with a specific unfavorable genetic alteration. The purpose of the study is to improve the outcome of this disease in infants.
This description comes directly from the study's public registry record.
Lieke van den Wildenberg · 0031 88 972 72 72 · trialmanagement@prinsesmaximacentrum.nl
Peggy Scholte-Van Houtem · 0031 88 972 72 72 · trialmanagement@prinsesmaximacentrum.nl
Always discuss trial participation with your own doctor first.
| Hospital de Pediatría S.A.M.I.C. "Juan P. Garrahan" | Buenos Aires, Argentina | Suspended |
| Australian and New Zealand Children's Haematology/Oncology Group | Clayton, Victoria, Australia | Recruiting |
| North Adelaide- Womens and Childrens Hospital | Adelaide, Australia | Recruiting |
| Monash Children's Hosptial | Clayton, Australia | Active Not Recruiting |
| New Lambton Heights- John Hunter Children's Hospital | New Lambton Heights, Australia | Recruiting |
| Royal Children's Hospital (Children's Cancer Centre) | Parkville, Australia | Active Not Recruiting |
| Perth Children's Hospital | Perth, Australia | Recruiting |
| Queensland Children's Hospital | South Brisbane, Australia | Active Not Recruiting |
| Sydney Childrens Hospital | Sydney, Australia | Recruiting |
| The Childrens Hospital at Westmead | Westmead, Australia | Recruiting |
| Medical University Of Graz | Graz, Austria | Recruiting |
| Medical University Of Innsbruck | Innsbruck, Austria | Recruiting |
+ 112 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05327894